After an initial analysis of clinical data back in May failed to demonstrate a statistically significant impact on the biomarkers associated with the disease, a re-analysis has found that the Alzheimer’s drug candidate developed by the biotech highlighted in today’s article did in fact demonstrate “statistically significant improvements in biomarkers of disease and cognition” – and shares of the company surged on the news. One 5-star analyst has now upgraded the stock from Hold to Buy – and sees upside potential of over 100%. For more on this stock, CLICK HERE.